<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363219">
  <stage>Registered</stage>
  <submitdate>30/10/2012</submitdate>
  <approvaldate>21/11/2013</approvaldate>
  <actrnumber>ACTRN12613001293752</actrnumber>
  <trial_identification>
    <studytitle>The importance of Microcirculation in Liver resection</studytitle>
    <scientifictitle>The importance of hepatic microcirculation and the pathophysiological role of endothelia-1 in major liver resection</scientifictitle>
    <utrn>U1111-1136-5261</utrn>
    <trialacronym>MERP-RESECTION</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Patients undergoing liver resection</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Forty patients undergoing major liver resection will be included in the study. Data regarding preoperative variables, intraoperative and postoperative variables are prospectively collected. 
A non-invasive device (called Sidestream Dark Field imaging), that allow for clinical observation of the microcirculation will be used before liver resection and 30 minutes after liver resection.. 
It is hand-held probe with a sterile extension for direct contact with liver parenchyma.  Portal vein and hepatic artery flow will be measured intraoperatively before resection and 30 min after liver resection.. 
Liver biopsies are performed before resection and 30 min after liver resection..  to assess Immunohystochemical intensity of ET-1 and other markers. The tissue to be acquired in this study will be obtained from surgical specimens taken from consented participants having liver resection.</interventions>
    <comparator>nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Correlation between microcirculation and portal vein and hepatic artery flow.</outcome>
      <timepoint>Before and after liver resection</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Liver functional test</outcome>
      <timepoint>Pre operative and Post operative day 1-3-5</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients undergoing major liver resection</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients undergoing minor resection</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/12/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Upper gastro-intestinal unit surgery unit</primarysponsorname>
    <primarysponsoraddress>Royal Prince Alfred hospital, missenden road
camperdown 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Upper gastro-intestinal surgery unit</fundingname>
      <fundingaddress>Royal Prince Alfred hospital, missenden road
camperdown 2050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Forty patients undergoing major liver resection will be included in the study. Data regarding preoperative variables, intraoperative and postoperative variables are prospectively collected. 
A non-invasive device (called Sidestream Dark Field imaging), that allow for clinical observation of the microcirculation will be used. 
It is hand-held probe with a sterile extension for direct contact with liver parenchyma.  Portal vein and hepatic artery flow will be measured intraoperatively. 
Liver biopsies are performed to assess Immunohystochemical intensity of ET-1 and other markers. The tissue to be acquired in this study will be obtained from surgical specimens taken from consented participants having liver resection.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics review Committee</ethicname>
      <ethicaddress>royal prince Alfred Hospita
Camperdown, 2050</ethicaddress>
      <ethicapprovaldate>20/03/2013</ethicapprovaldate>
      <hrec>hrec/c12/rpah/530</hrec>
      <ethicsubmitdate>31/10/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Carlo Pulitano</name>
      <address>Royal Prince Alfred Hospital
Missenden road
Camperdown 2050 NSW</address>
      <phone>+ 61 458 003 482</phone>
      <fax />
      <email>carlo.pulitano@gmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Carlo Pulitano</name>
      <address>Royal Prince Alfred Hospital
Missenden road
Camperdown 2050 NSW</address>
      <phone>+ 61 458 003 482</phone>
      <fax />
      <email>carlo.pulitano@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Carlo Pulitano</name>
      <address>Royal Prince Alfred Hospital
Missenden road
Camperdown 2050 NSW</address>
      <phone>+ 61 458 003 482</phone>
      <fax />
      <email>carlo.pulitano@gmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Carlo Pulitano</name>
      <address>Royal Prince Alfred Hospital
Missenden road
Camperdown 2050 NSW</address>
      <phone>+ 61 458 003 482</phone>
      <fax />
      <email>carlo.pulitano@gmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>